サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1764321

フックス内皮角膜ジストロフィーの世界市場レポート 2025年

Fuchs Endothelial Corneal Dystrophy Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.02円
フックス内皮角膜ジストロフィーの世界市場レポート 2025年
出版日: 2025年07月07日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

フックス内皮角膜ジストロフィー市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で2,514億7,000万米ドルに成長します。この予測期間における成長は、高度な画像診断の利用可能性の増加、医療費の増加、糖尿病や高血圧の罹患率の上昇、眼科専門クリニックの拡大、疾患の遺伝的・分子的メカニズムに関する研究の進展によって牽引されると予想されます。この期間に予想される主な動向には、再生医療の進歩、診断プロセスにおける人工知能の統合、生体工学角膜移植片の技術革新、手術技術の改善、角膜イメージングシステムにおける先端技術の採用などがあります。

角膜移植に対する需要の高まりは、今後数年間のフックス内皮角膜ジストロフィー（FECD）市場の成長を促進すると予想されています。角膜移植は、損傷したり病気になったりした角膜を健康なドナー組織と交換することで、視力と適切な眼球機能を回復させるものです。この需要は、視力喪失につながり外科的矯正を必要とする角膜障害の有病率の増加により増加しています。FECDは、角膜内皮を徐々に損傷し、最終的に視力を損ない、外科的介入を必要とすることにより、この需要に大きく寄与しています。例えば、2023年、米国アイバンク協会は、国内の角膜移植術が2.7％増加し、2022年の4万9,597件から2023年には5万925件に増加すると報告しています。このように、角膜移植のニーズの高まりがFECD市場の拡大に拍車をかけています。

フックス内皮角膜ジストロフィー（FECD）市場の主要企業は、角膜細胞の再生を促進し、視力を回復させることを目的としたRhoキナーゼ阻害剤などの革新的な治療を開発するため、臨床試験を優先しています。Rhoキナーゼ阻害薬は、Rhoキナーゼ経路を阻害することにより、細胞ストレスを軽減し、角膜内皮細胞の再生を促進する働きがあり、FECDの有望な治療選択肢となっています。例えば、日本の製薬会社である興和株式会社は、2023年4月、脱スメ膜手術後のFECD患者を対象に、K-321（リパスジル塩酸塩2水和物）点眼液の安全性と有効性を評価する国際共同第3相臨床試験を開始しました。本試験は、進行すると角膜移植を必要とすることが多いFECDの非外科的治療法の確立を目指すものです。本試験は、Rhoキナーゼ阻害剤の使用を緑内障治療以外にも拡大し、FECD治療におけるアンメット・クリニカル・ニーズに対応するための重要な前進となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界のフックス内皮角膜ジストロフィー：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界のフックス内皮角膜ジストロフィー市場：成長率分析
  • 世界のフックス内皮角膜ジストロフィー市場の実績：規模と成長、2019年～2024年
  • 世界のフックス内皮角膜ジストロフィー市場の予測：規模と成長、2024年～2029年、2034年
  • 世界のフックス内皮角膜ジストロフィー：総潜在市場規模（TAM）

第6章 市場セグメンテーション

  • 世界のフックス内皮角膜ジストロフィー市場：治療別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 光線療法角膜切除術
  • 羊膜移植
  • 前部間質穿刺
  • 結膜フラップ
  • 世界のフックス内皮角膜ジストロフィー市場：診断別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 角膜検査とグレーディング
  • 角膜断層撮影
  • 角膜厚測定
  • 角膜細胞数
  • その他の診断
  • 世界のフックス内皮角膜ジストロフィー市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 経口
  • 局所
  • その他の投与経路
  • 世界のフックス内皮角膜ジストロフィー市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院
  • 専門クリニック
  • ホームケア
  • その他のエンドユーザー
  • 世界のフックス内皮角膜ジストロフィー市場、光線療法角膜切除術の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • エキシマレーザーを用いた光線療法角膜切除術
  • フェムト秒レーザーを用いた光線療法角膜切除術
  • トポグラフィー誘導光線療法角膜切除術
  • 光線療法角膜切除術を伴う用手的上皮デブリードマン
  • 世界のフックス内皮角膜ジストロフィー市場、羊膜移植の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 凍結保存された羊膜
  • 脱水した羊膜
  • 単層膜移植
  • 多層膜移植
  • 世界のフックス内皮角膜ジストロフィー市場、前部間質穿刺のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 手動針穿刺
  • レーザー支援前部間質穿刺
  • パターンベースの穿刺
  • バンデージコンタクトレンズとの併用
  • 世界のフックス内皮角膜ジストロフィー市場、結膜フラップの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 全結膜皮弁
  • 部分的または扇状結膜皮弁
  • 円蓋ベースの皮弁
  • 輪部皮弁

第7章 地域別・国別分析

  • 世界のフックス内皮角膜ジストロフィー市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 世界のフックス内皮角膜ジストロフィー市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • フックス内皮角膜ジストロフィー市場：競合情勢
  • フックス内皮角膜ジストロフィー市場：企業プロファイル
    • Carl Zeiss Meditec Overview, Products and Services, Strategy and Financial Analysis
    • Santen Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Design Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Stealth BioTherapeutics Corp. Overview, Products and Services, Strategy and Financial Analysis
    • ProQR Therapeutics N.V. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Surrozen Inc.
  • Cellusion Inc.
  • Price Vision Group LLC
  • ActualEyes Inc.
  • Arctic Vision Limited
  • Aurion Biotech Inc.
  • Emmecell Inc.
  • Invirsa Inc.
  • KeraMed Inc.
  • Kowa Company Ltd.
  • Kuria Therapeutics Inc.
  • Massachusetts Eye and Ear
  • MediciBIO Co. LTD.
  • Prime Medicine Inc.
  • Trefoil Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • フックス内皮角膜ジストロフィー市場2029年：新たな機会を提供する国
  • フックス内皮角膜ジストロフィー市場2029年：新たな機会を提供するセグメント
  • フックス内皮角膜ジストロフィー市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35910

Fuchs endothelial corneal dystrophy (FECD) is a progressive eye condition that affects the endothelium, the innermost layer of the cornea. It involves the gradual degeneration of endothelial cells, which are critical for keeping the cornea clear by removing excess fluid. As these cells are lost, fluid accumulates in the cornea, leading to swelling, blurred vision, and, in more severe cases, pain.

Primary treatment options for FECD include phototherapeutic keratectomy, amniotic membrane transplants, anterior stromal puncture, and conjunctival flaps. Phototherapeutic keratectomy (PTK) is a laser-based surgical technique used to remove surface-level corneal irregularities or opacities, helping to restore vision and alleviate discomfort associated with corneal diseases. Diagnosis commonly involves corneal examinations and grading, corneal tomography, pachymetry, and endothelial cell counts, among other methods. Treatments may be administered via oral, topical, or other routes and are delivered in a range of healthcare settings, including hospitals, specialty clinics, homecare, and others.

The fuchs endothelial corneal dystrophy market research report is one of a series of new reports from The Business Research Company that cover fuchs endothelial corneal dystrophy market statistics, including the fuchs endothelial corneal dystrophy industry's global market size, regional shares, competitors with the fuchs endothelial corneal dystrophy market share, detailed fuchs endothelial corneal dystrophy market segments, market trends and opportunities, and any further data you may need to thrive in the fuchs endothelial corneal dystrophy market. This fuchs endothelial corneal dystrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fuchs endothelial corneal dystrophy market size has grown strongly in recent years. It will grow from $171.48 billion in 2024 to $185.45 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. Growth during the historic period can be attributed to the rising prevalence of age-related eye disorders, increasing demand for corneal transplants, improved awareness and diagnosis rates, greater adoption of minimally invasive surgical procedures, and growing investments in regenerative medicine.

The fuchs endothelial corneal dystrophy market size is expected to see strong growth in the next few years. It will grow to $251.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. Growth in the forecast period is expected to be driven by the increasing availability of advanced diagnostic imaging, rising healthcare expenditure, higher incidence of diabetes and hypertension, expanding reach of specialty eye clinics, and advancing research into the genetic and molecular mechanisms of the disease. Key trends anticipated during this period include progress in regenerative medicine, integration of artificial intelligence in diagnostic processes, innovations in bioengineered corneal grafts, improvements in surgical techniques, and the adoption of advanced technologies in corneal imaging systems.

The rising demand for corneal transplants is expected to drive the growth of the fuchs endothelial corneal dystrophy (FECD) market in the coming years. Corneal transplants involve replacing a damaged or diseased cornea with healthy donor tissue to restore vision and proper eye function. This demand is increasing due to the growing prevalence of corneal disorders that lead to vision loss and require surgical correction. FECD contributes significantly to this demand by progressively damaging the corneal endothelium, ultimately impairing vision and necessitating surgical intervention. For example, in 2023, the Eye Bank Association of America reported a 2.7% increase in domestic keratoplasty procedures, rising from 49,597 in 2022 to 50,925 in 2023. Thus, the growing need for corneal transplants is fueling the expansion of the FECD market.

Leading companies in the fuchs endothelial corneal dystrophy (FECD) market are prioritizing clinical trials to develop innovative treatments such as Rho kinase inhibitors, aimed at enhancing corneal cell regeneration and restoring vision. Rho kinase inhibitors work by blocking the Rho kinase pathway, which helps reduce cellular stress and promotes the regeneration of corneal endothelial cells, making them a promising therapeutic option for FECD. For example, in April 2023, Kowa Company, Ltd., a Japan-based pharmaceutical firm, initiated a global Phase 3 clinical trial to assess the safety and efficacy of K-321 (Ripasudil Hydrochloride Dihydrate) ophthalmic solution in patients with FECD following descemetorhexis. This trial seeks to establish a non-surgical treatment alternative for FECD, which often requires corneal transplantation in advanced stages. The study represents a significant step forward in expanding the use of Rho kinase inhibitors beyond glaucoma treatment and addressing the unmet clinical needs in FECD therapy.

In May 2022, Santen Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, entered into a partnership with ActualEyes Inc. to jointly develop and advance innovative therapeutic candidates for Fuchs endothelial corneal dystrophy. As part of this collaboration, they initiated the PHANTOM Phase IIa clinical trial. ActualEyes Inc., also based in Japan, is a biotechnology company focused on creating treatments for Fuchs endothelial corneal dystrophy.

Major players in the fuchs endothelial corneal dystrophy market are Carl Zeiss Meditec, Santen Pharmaceutical Co. Ltd., Design Therapeutics Inc., Stealth BioTherapeutics Corp., ProQR Therapeutics N.V., Surrozen Inc., Cellusion Inc., Price Vision Group LLC, ActualEyes Inc., Arctic Vision Limited, Aurion Biotech Inc., Emmecell Inc., Invirsa Inc., KeraMed Inc., Kowa Company Ltd., Kuria Therapeutics Inc., Massachusetts Eye and Ear, MediciBIO Co. LTD., Prime Medicine Inc., and Trefoil Therapeutics.

North America was the largest region in the fuchs endothelial corneal dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fuchs endothelial corneal dystrophy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fuchs endothelial corneal dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fuchs endothelial corneal dystrophy market includes revenues earned by entities by providing services such as diagnosis services, corneal pachymetry, specular microscopy, slit-lamp examination, and visual acuity testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The fuchs endothelial corneal dystrophy market also includes sales of artificial tears, hypertonic saline drops, ointments, bandage contact lenses, and endothelial keratoplasty kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fuchs Endothelial Corneal Dystrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fuchs endothelial corneal dystrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fuchs endothelial corneal dystrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fuchs endothelial corneal dystrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Phototherapeutic Keratectomy; Amniotic Membrane Transplants; Anterior Stromal Puncture; Conjunctival Flaps
  • 2) By Diagnosis: Cornea Examination And Grading; Corneal Tomography; Corneal Pachymetry; Corneal Cell Count; Other Diagnosis
  • 3) By Route Of Administration: Oral; Topical; Other Routes Of Administration
  • 4) By End-Users: Hospital; Specialty Clinics; Homecare; Other End-Users

Subsegments

  • 1) By Phototherapeutic Keratectomy: Excimer Laser-Based Phototherapeutic Keratectomy; Femtosecond Laser-Assisted Phototherapeutic Keratectomy; Topography-Guided Phototherapeutic Keratectomy; Manual Epithelial Debridement With Phototherapeutic Keratectomy
  • 2) By Amniotic Membrane Transplants: Cryopreserved Amniotic Membrane; Dehydrated Amniotic Membrane; Single-Layer Membrane Transplant; Multi-Layer Membrane Transplant
  • 3) By Anterior Stromal Puncture: Manual Needle-Based Puncture; Laser-Assisted Anterior Stromal Puncture; Pattern-Based Puncture; Combination With Bandage Contact Lens
  • 4) By Conjunctival Flaps: Total Conjunctival Flap; Partial Or Sectoral Conjunctival Flap; Fornix-Based Flap; Limbal-Based Flap
  • Companies Mentioned: Carl Zeiss Meditec; Santen Pharmaceutical Co. Ltd.; Design Therapeutics Inc.; Stealth BioTherapeutics Corp.; ProQR Therapeutics N.V.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fuchs Endothelial Corneal Dystrophy Market Characteristics

3. Fuchs Endothelial Corneal Dystrophy Market Trends And Strategies

4. Fuchs Endothelial Corneal Dystrophy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fuchs Endothelial Corneal Dystrophy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Fuchs Endothelial Corneal Dystrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Fuchs Endothelial Corneal Dystrophy Market Growth Rate Analysis
  • 5.4. Global Fuchs Endothelial Corneal Dystrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Fuchs Endothelial Corneal Dystrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Fuchs Endothelial Corneal Dystrophy Total Addressable Market (TAM)

6. Fuchs Endothelial Corneal Dystrophy Market Segmentation

  • 6.1. Global Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Phototherapeutic Keratectomy
  • Amniotic Membrane Transplants
  • Anterior Stromal Puncture
  • Conjunctival Flaps
  • 6.2. Global Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cornea Examination And Grading
  • Corneal Tomography
  • Corneal Pachymetry
  • Corneal Cell Count
  • Other Diagnosis
  • 6.3. Global Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Topical
  • Other Routes Of Administration
  • 6.4. Global Fuchs Endothelial Corneal Dystrophy Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital
  • Specialty Clinics
  • Homecare
  • Other End-Users
  • 6.5. Global Fuchs Endothelial Corneal Dystrophy Market, Sub-Segmentation Of Phototherapeutic Keratectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Excimer Laser-Based Phototherapeutic Keratectomy
  • Femtosecond Laser-Assisted Phototherapeutic Keratectomy
  • Topography-Guided Phototherapeutic Keratectomy
  • Manual Epithelial Debridement With Phototherapeutic Keratectomy
  • 6.6. Global Fuchs Endothelial Corneal Dystrophy Market, Sub-Segmentation Of Amniotic Membrane Transplants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cryopreserved Amniotic Membrane
  • Dehydrated Amniotic Membrane
  • Single-Layer Membrane Transplant
  • Multi-Layer Membrane Transplant
  • 6.7. Global Fuchs Endothelial Corneal Dystrophy Market, Sub-Segmentation Of Anterior Stromal Puncture, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Manual Needle-Based Puncture
  • Laser-Assisted Anterior Stromal Puncture
  • Pattern-Based Puncture
  • Combination With Bandage Contact Lens
  • 6.8. Global Fuchs Endothelial Corneal Dystrophy Market, Sub-Segmentation Of Conjunctival Flaps, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Total Conjunctival Flap
  • Partial Or Sectoral Conjunctival Flap
  • Fornix-Based Flap
  • Limbal-Based Flap

7. Fuchs Endothelial Corneal Dystrophy Market Regional And Country Analysis

  • 7.1. Global Fuchs Endothelial Corneal Dystrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Fuchs Endothelial Corneal Dystrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fuchs Endothelial Corneal Dystrophy Market

  • 8.1. Asia-Pacific Fuchs Endothelial Corneal Dystrophy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fuchs Endothelial Corneal Dystrophy Market

  • 9.1. China Fuchs Endothelial Corneal Dystrophy Market Overview
  • 9.2. China Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fuchs Endothelial Corneal Dystrophy Market

  • 10.1. India Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fuchs Endothelial Corneal Dystrophy Market

  • 11.1. Japan Fuchs Endothelial Corneal Dystrophy Market Overview
  • 11.2. Japan Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fuchs Endothelial Corneal Dystrophy Market

  • 12.1. Australia Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fuchs Endothelial Corneal Dystrophy Market

  • 13.1. Indonesia Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fuchs Endothelial Corneal Dystrophy Market

  • 14.1. South Korea Fuchs Endothelial Corneal Dystrophy Market Overview
  • 14.2. South Korea Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fuchs Endothelial Corneal Dystrophy Market

  • 15.1. Western Europe Fuchs Endothelial Corneal Dystrophy Market Overview
  • 15.2. Western Europe Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fuchs Endothelial Corneal Dystrophy Market

  • 16.1. UK Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fuchs Endothelial Corneal Dystrophy Market

  • 17.1. Germany Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fuchs Endothelial Corneal Dystrophy Market

  • 18.1. France Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fuchs Endothelial Corneal Dystrophy Market

  • 19.1. Italy Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fuchs Endothelial Corneal Dystrophy Market

  • 20.1. Spain Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fuchs Endothelial Corneal Dystrophy Market

  • 21.1. Eastern Europe Fuchs Endothelial Corneal Dystrophy Market Overview
  • 21.2. Eastern Europe Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fuchs Endothelial Corneal Dystrophy Market

  • 22.1. Russia Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fuchs Endothelial Corneal Dystrophy Market

  • 23.1. North America Fuchs Endothelial Corneal Dystrophy Market Overview
  • 23.2. North America Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fuchs Endothelial Corneal Dystrophy Market

  • 24.1. USA Fuchs Endothelial Corneal Dystrophy Market Overview
  • 24.2. USA Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fuchs Endothelial Corneal Dystrophy Market

  • 25.1. Canada Fuchs Endothelial Corneal Dystrophy Market Overview
  • 25.2. Canada Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fuchs Endothelial Corneal Dystrophy Market

  • 26.1. South America Fuchs Endothelial Corneal Dystrophy Market Overview
  • 26.2. South America Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fuchs Endothelial Corneal Dystrophy Market

  • 27.1. Brazil Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fuchs Endothelial Corneal Dystrophy Market

  • 28.1. Middle East Fuchs Endothelial Corneal Dystrophy Market Overview
  • 28.2. Middle East Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fuchs Endothelial Corneal Dystrophy Market

  • 29.1. Africa Fuchs Endothelial Corneal Dystrophy Market Overview
  • 29.2. Africa Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Fuchs Endothelial Corneal Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fuchs Endothelial Corneal Dystrophy Market Competitive Landscape And Company Profiles

  • 30.1. Fuchs Endothelial Corneal Dystrophy Market Competitive Landscape
  • 30.2. Fuchs Endothelial Corneal Dystrophy Market Company Profiles
    • 30.2.1. Carl Zeiss Meditec Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Santen Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Design Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Stealth BioTherapeutics Corp. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. ProQR Therapeutics N.V. Overview, Products and Services, Strategy and Financial Analysis

31. Fuchs Endothelial Corneal Dystrophy Market Other Major And Innovative Companies

  • 31.1. Surrozen Inc.
  • 31.2. Cellusion Inc.
  • 31.3. Price Vision Group LLC
  • 31.4. ActualEyes Inc.
  • 31.5. Arctic Vision Limited
  • 31.6. Aurion Biotech Inc.
  • 31.7. Emmecell Inc.
  • 31.8. Invirsa Inc.
  • 31.9. KeraMed Inc.
  • 31.10. Kowa Company Ltd.
  • 31.11. Kuria Therapeutics Inc.
  • 31.12. Massachusetts Eye and Ear
  • 31.13. MediciBIO Co. LTD.
  • 31.14. Prime Medicine Inc.
  • 31.15. Trefoil Therapeutics

32. Global Fuchs Endothelial Corneal Dystrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fuchs Endothelial Corneal Dystrophy Market

34. Recent Developments In The Fuchs Endothelial Corneal Dystrophy Market

35. Fuchs Endothelial Corneal Dystrophy Market High Potential Countries, Segments and Strategies

  • 35.1 Fuchs Endothelial Corneal Dystrophy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Fuchs Endothelial Corneal Dystrophy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Fuchs Endothelial Corneal Dystrophy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer